18PTKI pazopanib impaires immunostimulatory properties of monocytes: Implication for monocyte-derived DC-based anti-cancer vaccine preparation
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F16%3A00114976" target="_blank" >RIV/00216224:14110/16:00114976 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1093/annonc/mdw525.18" target="_blank" >http://dx.doi.org/10.1093/annonc/mdw525.18</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1093/annonc/mdw525.18" target="_blank" >10.1093/annonc/mdw525.18</a>
Alternative languages
Result language
angličtina
Original language name
18PTKI pazopanib impaires immunostimulatory properties of monocytes: Implication for monocyte-derived DC-based anti-cancer vaccine preparation
Original language description
We manufacture fully personalized monocyte-derived dendritic cell-based vaccines that are evaluated in investigator-initiated clinical trial „Combined antitumor therapy with ex vivo manipulated dendritic cells producing interleukin-12 in children, adolescents and young adults with progressive, recurrent of primarily metastatic high-risk tumours”. Immunobiological part of quality control (QC) of DC batches revealed variability in immunostimulatory properties. We analyzed DC parametres within the context of patients medical history and explore the effect of anti-cancer compound on monocyte functional properties.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
<a href="/en/project/LM2015090" target="_blank" >LM2015090: Czech National Node to the European Clinical Research Infrastructure Network</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů